{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:05:03Z","timestamp":1769709903926,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,28]]},"DOI":"10.7759\/cureus.102522","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:07:35Z","timestamp":1769666855000},"source":"Crossref","is-referenced-by-count":0,"title":["Add-On Spironolactone for Persistent Proteinuria After Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Patients With Diabetic Kidney Disease: A Retrospective Observational Study"],"prefix":"10.7759","author":[{"given":"Seigo","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunio","family":"Hieshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Kurinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S011","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S239-51. 10.2337\/dc25-S011","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2009.11","article-title":"Cardiovascular implications of proteinuria: an indicator of chronic kidney disease","volume":"6","author":"Agrawal V","year":"2009","unstructured":"Agrawal V, Marinescu V, Agarwal M, McCullough PA. Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nat Rev Cardiol. 2009, 6:301-11. 10.1038\/nrcardio.2009.11","journal-title":"Nat Rev Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal R","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJ, et al.. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025, 393:533-43. 10.1056\/NEJMoa2410659","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Piperidou A","year":"2019","unstructured":"Piperidou A, Sarafidis P, Boutou A, et al.. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019, 37:1334-43. 10.1097\/HJH.0000000000002050","journal-title":"J Hypertens"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3171","article-title":"SGLT2 inhibition to address the unmet needs in diabetic nephropathy","volume":"35","author":"Barutta F","year":"2019","unstructured":"Barutta F, Bernardi S, Gargiulo G, Durazzo M, Gruden G. SGLT2 inhibition to address the unmet needs in diabetic nephropathy. Diabetes Metab Res Rev. 2019, 35:e3171. 10.1002\/dmrr.3171","journal-title":"Diabetes Metab Res Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.21.285","article-title":"Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors","volume":"41","author":"Chan AT","year":"2022","unstructured":"Chan AT, Tang SC. Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors. Kidney Res Clin Pract. 2022, 41:682-98. 10.23876\/j.krcp.21.285","journal-title":"Kidney Res Clin Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou A","year":"2001","unstructured":"Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001, 345:925-6. 10.1056\/NEJM200109203451215","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021694","article-title":"Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis","volume":"99","author":"Chen C","year":"2020","unstructured":"Chen C, Zhu XY, Li D, Lin Q, Zhou K. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2020, 99:e21694. 10.1097\/MD.0000000000021694","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo S","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al.. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009, 53:982-92. 10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2011.04.002","article-title":"Implications of proteinuria: CKD progression and cardiovascular outcomes","volume":"18","author":"Sarnak MJ","year":"2011","unstructured":"Sarnak MJ, Astor BC. Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis. 2011, 18:258-66. 10.1053\/j.ackd.2011.04.002","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof P","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017, 234:T125-40. 10.1530\/JOE-16-0600","journal-title":"J Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.011629","article-title":"Mineralocorticoid receptor antagonists in heart failure: an update","volume":"17","author":"Ferreira JP","year":"2024","unstructured":"Ferreira JP, Pitt B, Zannad F. Mineralocorticoid receptor antagonists in heart failure: an update. Circ Heart Fail. 2024, 17:12. 10.1161\/CIRCHEARTFAILURE.124.011629","journal-title":"Circ Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in Clinical Pharmacology","volume":"68","author":"Jaisser F","year":"2016","unstructured":"Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in Clinical Pharmacology. Pharmacol Rev. 2016, 68:49-75. 10.1124\/pr.115.011106","journal-title":"Pharmacol Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(01)80115-3","article-title":"Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications","volume":"37","author":"Epstein M","year":"2001","unstructured":"Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis. 2001, 37:677-88. 10.1016\/S0272-6386(01)80115-3","journal-title":"Am J Kidney Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad144","article-title":"Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes","volume":"108","author":"Oiwa A","year":"2023","unstructured":"Oiwa A, Hiwatashi D, Takeda T, et al.. Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes. J Clin Endocrinol Metab. 2023, 108:2203-10. 10.1210\/clinem\/dgad144","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards NC","year":"2012","unstructured":"Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol. 2012, 73:447-54. 10.1111\/j.1365-2125.2011.04102.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown NJ","year":"2013","unstructured":"Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013, 9:459-69. 10.1038\/nrneph.2013.110","journal-title":"Nat Rev Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata S","year":"2007","unstructured":"Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007, 49:355-64. 10.1161\/01.HYP.0000255636.11931.a2","journal-title":"Hypertension"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90646.2008","article-title":"Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat","volume":"296","author":"Whaley-Connell A","year":"2009","unstructured":"Whaley-Connell A, Habibi J, Wei Y, et al.. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol. 2009, 296:F1013-22. 10.1152\/ajprenal.90646.2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq750","article-title":"Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production","volume":"26","author":"Toyonaga J","year":"2011","unstructured":"Toyonaga J, Tsuruya K, Ikeda H, et al.. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant. 2011, 26:2475-84. 10.1093\/ndt\/gfq750","journal-title":"Nephrol Dial Transplant"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae027","article-title":"Glomerular hyperfiltration as a therapeutic target for CKD","volume":"39","author":"Kanbay M","year":"2024","unstructured":"Kanbay M, Copur S, Bakir CN, Covic A, Ortiz A, Tuttle KR. Glomerular hyperfiltration as a therapeutic target for CKD. Nephrol Dial Transplant. 2024, 39:1228-38. 10.1093\/ndt\/gfae027","journal-title":"Nephrol Dial Transplant"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet M","year":"2010","unstructured":"Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010, 6:261-73. 10.1038\/nrneph.2010.30","journal-title":"Nat Rev Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.10r07cr","article-title":"Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney","volume":"115","author":"Rafiq K","year":"2011","unstructured":"Rafiq K, Hitomi H, Nakano D, Nishiyama A. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharmacol Sci. 2011, 115:1-7. 10.1254\/jphs.10r07cr","journal-title":"J Pharmacol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han SY","year":"2006","unstructured":"Han SY, Kim CH, Kim HS, et al.. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006, 17:1362-72. 10.1681\/ASN.2005111196","journal-title":"J Am Soc Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455563-add-on-spironolactone-for-persistent-proteinuria-after-sodium-glucose-cotransporter-2-inhibitor-therapy-in-patients-with-diabetic-kidney-disease-a-retrospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:07:36Z","timestamp":1769666856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455563-add-on-spironolactone-for-persistent-proteinuria-after-sodium-glucose-cotransporter-2-inhibitor-therapy-in-patients-with-diabetic-kidney-disease-a-retrospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.102522","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}